Search

Filters
Clear All
  • 14
  • 49
  • 3
  • 707

Phase

  • 1
  • 14
  • 11
  • 49
  • 9
  • 56
  • 6
  • 593
  • 705
  • 317

Found 773 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Mother Baby Study

Mother Baby Study

R
Rupa Radhakrishnan, MD
18-100 years
Female
ARE YOU PREGNANT? - If yes, consider joining our study!   Researchers at Indiana University School of Medicine are looking for expecting mothers to volunteer to take part in a study looking to improve outcomes  in mothers who have taken opioids during pregnancy and their newborn babies, Researchers also want to learn about …

Title: A Phase 2 multicenter open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS) non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)

K
Kristy Pilbeam
1-18 years
All genders
The purpose of this study is to assess of activity of eribulin mesylate in pediatric subjects with relapsed/refractory RMS, NRSTS or EWS.

A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia

S
Sandeep Batra, MD
8-15 years
All genders
This randomized clinical trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with newly diagnosed acute lymphoblastic leukemia that shows a decrease in or disappearance of signs and symptoms. Regular physical activity after receiving treatment for cancer may help to maintain …

A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139

N
Nasser Hanna, MD
18-100 years
All genders
The purpose of this study is to estimate the progression free survival (PFS) of the combination of Carboplatin plus Pemetrexed plus Atezolizumab plus Bevacizumab for patients with stage IV non-squamous NSCLC who are chemotherapy and immunotherapy naive.

Effect of low intensity vibration (LIV) on aromatase inhibitor- induced musculoskeletal dysfunction in early stage breast cancer survivors

T
Tarah Ballinger, MD
18-100 years
Female
A type of breast cancer medicine called aromatase inhibitors (AI) causes muscle weakness and bone loss in patients. This research is being done to test whether low intensity vibration (LIV) can prevent the loss of muscle and bone strength in patients receiving AIs.

Enhancing Prospective Thinking in Early Recovery

B
Brandon Oberlin
18-100 years
All genders
The purpose of this study is to better understand what factors, demographic characteristics, and interventions predict better recovery-related outcomes.

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

N
Nabil Adra, MD
18-100 years
All genders
The purpose of this study is to compare any good and bad effects of using Atezolizumab along with the usual chemotherapy after progression with PD-1 or PD-L1 Inhibitor for individuals with urothelial carcinoma (cancer of the urinary tract).

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors

P
Patrick Loehrer, MD
18-100 years
All genders
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …

Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release

J
Jodi Skiles
All genders
The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release where no overwhelming safety concerns has been …

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations

S
Sandeep Batra, MD
3-25 years
All genders
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.
401 - 410 of 773